A carregar...
Publicação
What are the effects of rhEPO, ARA-290, TDZD-8 and 5-AIQ on random pattern flaps?
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 289.45 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
Introdução: Os retalhos são frequentemente usados na Cirurgia Plástica e Reconstrutiva para restaurar a aparência e a função dos tecidos nas mais variadas circunstâncias. A perda dos retalhos é sempre uma situação constrangedora, quer para o paciente quer para a equipa de médicos, representando um aumento no tempo de hospitalização e subsequentemente nos custos do tratamento. Face ao exposto, os trabalhos de investigação focam-se na descoberta de agentes que possam melhorar as taxas de sobrevivência dos retalhos. Algumas das hipóteses são a eritropoietina humana recombinante (rhEPO), o ARA-290, a 4-benzyl-2-methyl-1,2,4-tiadiazolidine-3,5-diona (TDZD-8) e a 5-aminoisoquinolinona (5-AIQ). As evidências têm demonstrado a capacidade protectora destes agentes em eventos de isquémia aguda e isquémia-reperfusão, na estimulação da angiogénese e na modulação das respostas inflamatórias. Objectivos: O principal objectivo deste projecto de investigação é avaliar os efeitos da rhEPO, ARA-290, TDZD-8 e 5-AIQ na sobrevivência dos retalhos. Metodologia: Os ratos serão submetidos a um retalho cutâneo dorsal, utilizando a técnica modificada de McFarlane. Posteriormente, os ratos serão divididos em dois grupos: o controlo (placebo) e o activo (rhEPO, ARA-290, TDZD-8 e 5-AIQ). Os fármacos serão administrados após encerramento dos retalhos por três dias consecutivos. Ao sétimo dia, os retalhos de ambos os grupos serão avaliados. Também serão feitas análises imunohistoquímicas e determinações dos níveis séricos de mediadores inflamatórios e marcadores de lesão celular. Resultados: São expectáveis melhores taxas de sobrevivência e menores concentrações séricas de mediadores inflamatórios e marcadores de lesão celular no grupo activo. Conclusão: Face à capacidade cito-protectora dos diferentes agentes farmacológicos nas mais diversas circunstâncias e órgãos, é esperada uma melhoria significativa na viabilidade dos retalhos.
Introduction: Random pattern flaps are frequently used in Plastic and Reconstructive Surgery to restore the appearance and function in the most widely cases. The loss of flaps is always a distressing occasion for the patient and for the team, representing an increase in the hospitalization time and, ultimately, in the medical costs. Therefore, research is focused on finding agents that could improve the flap tissues survival rates. Some of those hypothesis are the use of recombinant human erythropoietin (rhEPO), ARA-290, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8) and 5-aminoisoquinolinone (5-AIQ). Experiments have demonstrated its protective capacity in acute ischemia and ischemia-reperfusion events, in the stimulation of angiogenesis, in the modulation of inflammatory responses among others. Objectives: The main objective of the proposed investigation is to evaluate the effects of rhEPO, ARA-290, TDZD-8 and 5-AIQ on random skin flaps survival. Methodology: Performance of caudally based random pattern skin flaps in rats, using the modified McFarlane technique. Division of the rats into control (placebo) and active (rhEPO, ARA-290, TDZD-8, 5-AIQ) groups. Test drugs are to be administered after flap closure for three consecutive days. Evaluation of the flaps in the groups on day seven. Immunohistochemical analysis and plasmatic lesion markers and inflammatory mediators’ serum levels determinations. Results: We expect to obtain better survival rates and less seric concentrations of lesion markers and inflammatory mediators on the active group flaps. Conclusion: Facing the cytoprotection ability of the different pharmacological agents in the most different circumstances and organs, it is suggested that they will improve the viability of the random flaps in a significant manner.
Introduction: Random pattern flaps are frequently used in Plastic and Reconstructive Surgery to restore the appearance and function in the most widely cases. The loss of flaps is always a distressing occasion for the patient and for the team, representing an increase in the hospitalization time and, ultimately, in the medical costs. Therefore, research is focused on finding agents that could improve the flap tissues survival rates. Some of those hypothesis are the use of recombinant human erythropoietin (rhEPO), ARA-290, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8) and 5-aminoisoquinolinone (5-AIQ). Experiments have demonstrated its protective capacity in acute ischemia and ischemia-reperfusion events, in the stimulation of angiogenesis, in the modulation of inflammatory responses among others. Objectives: The main objective of the proposed investigation is to evaluate the effects of rhEPO, ARA-290, TDZD-8 and 5-AIQ on random skin flaps survival. Methodology: Performance of caudally based random pattern skin flaps in rats, using the modified McFarlane technique. Division of the rats into control (placebo) and active (rhEPO, ARA-290, TDZD-8, 5-AIQ) groups. Test drugs are to be administered after flap closure for three consecutive days. Evaluation of the flaps in the groups on day seven. Immunohistochemical analysis and plasmatic lesion markers and inflammatory mediators’ serum levels determinations. Results: We expect to obtain better survival rates and less seric concentrations of lesion markers and inflammatory mediators on the active group flaps. Conclusion: Facing the cytoprotection ability of the different pharmacological agents in the most different circumstances and organs, it is suggested that they will improve the viability of the random flaps in a significant manner.
Descrição
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2015
Palavras-chave
Cirurgia plástica Retalhos Melhoria da sobrevida